Market Overview

CardioDx Announces Clinical and Scientific Presentations at the American Heart Association Scientific Sessions 2012


CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, today announced that data related to Corus® CAD, the company's blood-based gene expression test to safely, accurately and conveniently help clinicians determine whether or not patient symptoms are due to obstructive coronary artery disease (CAD), will be presented at the American Heart Association Scientific Sessions 2012 conference taking place November 3-7 in Los Angeles, Calif.

Corus CAD is a decision-making tool that can help primary care clinicians and cardiologists exclude obstructive CAD as the cause of a stable nondiabetic patient's symptoms. The test involves a routine blood draw conveniently administered in the clinician's office, and does not expose patients to risk of radiation or imaging agent intolerance. It is the only sex-specific test for obstructive CAD, accounting for critical biological differences between men and women. Corus CAD has now been used to assess more than 31,000 U.S. patients.

Clinical and scientific presentations featuring Corus CAD data at the meeting include:

  • On Sunday, November 4 from 3:00 to 4:30 p.m. PT in Kentia Hall, Szilard Voros, M.D., Associate Professor of Medicine/Cardiology and Radiology at Stony Brook University, will present a poster entitled “Peripheral Blood Gene Expression Reflects Differences Between Coronary Artery Calcification and Stenosis as Assessed by Coronary Artery Calcium Scanning and CT Angiography.” This study analyzed the relationship of individual genes included in the Corus CAD algorithm with coronary calcium, maximum percent stenosis and plaque composition data from patients enrolled in the PREDICT and COMPASS multicenter studies.
  • On Monday, November 5 at 4:45 p.m. PT in Room 304ab, Dr. Voros will present an oral presentation entitled “Coronary Artery Plaque Burden and Stenosis by Cardiovascular CT Correlate with Peripheral Gene Expression in 614 Patients.” This study evaluated the association between coronary plaque burden and maximum percent stenosis with Corus CAD test scores in patients enrolled in the PREDICT and COMPASS multicenter studies.
  • On Wednesday, November 7 from 9:00 to 11:00 a.m. PT in Kentia Hall, Kelly Parsons, Ph.D., Senior Research Manager at Express Scripts, will present a poster entitled “Physicians' Use of a Gene Expression Test was Associated with Increased Utilization and Medication Adherence among Patients Prescribed Lipid-Lowering Therapy.” The study evaluated whether Corus CAD test score influenced patient adherence to prescribed lipid-lowering medications.

The Corus CAD gene expression test has been validated in three independent patient cohorts enrolled as part of two prospective, multicenter studies, PREDICT and COMPASS. The PREDICT study first validated the ability of Corus CAD to assess whether or not a stable, nondiabetic patient's symptoms are due to obstructive CAD. In the COMPASS validation study, Corus CAD demonstrated very high negative predictive value (96 percent) in a patient population reflecting the test's intended-use population, outperforming myocardial perfusion imaging (MPI) in diagnostic accuracy and negative predictive value. In these studies, Corus CAD was validated using CT angiography and the gold standard for diagnosis of CAD, invasive coronary angiography.

About Corus CAD

With a simple blood draw, Corus CAD can safely, accurately and conveniently help primary care clinicians and cardiologists assess whether or not a stable nondiabetic patient's symptoms are due to obstructive coronary artery disease (CAD), enabling many patients to avoid unnecessary invasive procedures and exposure to imaging-related radiation risks or imaging agent intolerance. The test has been clinically validated in multiple independent patient cohorts, including two prospective, multicenter U.S. studies, PREDICT and COMPASS. Additionally, a retrospective, multicenter chart review study and the prospective IMPACT trial at Vanderbilt University demonstrated that Corus CAD use yields statistically significant and clinically relevant changes in patient management decisions in both primary care and cardiology settings. Corus CAD has been used commercially by clinicians in more than 31,000 patients and is a covered benefit for more than 40 million Medicare enrollees in the U.S.

Corus CAD has also been recognized by The Wall Street Journal's Technology Innovation Awards, honored as a Gold Edison Award recipient, and named one of TIME's Top Ten Medical Breakthroughs. CardioDx was recently honored as one of FierceMedicalDevices' “Fierce 15” most promising privately held medical device and diagnostic companies.

The Corus CAD test is intended for use in nondiabetic stable patients who present with typical or atypical symptoms suggestive of CAD, with no known history of CAD, have no prior myocardial infarction (MI) or revascularization procedure, and are not currently taking steroids, immunosuppressive agents or chemotherapeutic agents.

About CardioDx

CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, is committed to developing clinically validated tests that empower clinicians to better tailor care to each individual patient. Strategically focused on coronary artery disease, cardiac arrhythmia and heart failure, CardioDx is poised to expand patient access and improve healthcare quality and efficiency through the commercialization of genomic technologies. For more information, please visit

For CardioDx, Inc.
Nicole Osmer, 650-454-0504

View Comments and Join the Discussion!